HPLC Peptide Purity: What Clinic Buyers Should Know
Learn what an HPLC purity result can and cannot establish, including method limits, identity, strength, and the need for separate finished-product evidence.
For facility-specific purchasing requirements, visit our medical clinics sourcing guide. This article covers procurement, not treatment protocols.
Understand the measurement
HPLC separates components under a defined analytical method. A reported area percentage describes detected signals under those conditions; it is not a universal measurement of every possible impurity or quality attribute.
Do not treat 99% as a clinical guarantee
A high reported purity does not establish sterility, endotoxin suitability, dose strength, stability, or lawful clinical use. Nor does it establish that the preparation is effective for an advertised condition. Avoid qualifying a supplier on a single headline percentage.
Ask for the method and specification
The report should identify the test, lot, result, units where applicable, and acceptance criteria. Your qualified reviewer may need additional analytical information to interpret related substances or unresolved peaks. Similar percentages from different methods may not be directly comparable.
Keep identity and assay separate
Ask how identity is established and how strength or content is determined. Do not convert a chromatographic area percentage into a mass content or labeled concentration without appropriate supporting evidence.
Evaluate the finished preparation
Confirm whether the result applies to an ingredient or the received product. Review the additional records required for that preparation, including relevant sterility and endotoxin evidence. Use the COA guide for a structured document review.
What to do next
Record unresolved questions and the evidence your clinical or quality reviewer needs before ordering. Use the medical clinics purchasing page to prepare a facility-specific inquiry. Product mentions do not confirm stock, a legal supply pathway, or suitability for patient care.
Regulatory sources and purchasing limits
Compounded drugs are not FDA-approved. Facility registration does not establish approval or eligibility for every preparation. Verify the exact product, source, applicable federal requirements, and state rules before ordering. This is procurement education, not medical or legal advice.
- FDA: bulk substances used under section 503B, including restrictions and interim policies.
- FDA: GLP-1 compounding and shortage updates.
- FDA: safety concerns for certain compounding substances.